Atomo Diagnostics Secures Major Order for HIV Self-Tests in Australia

The latest update is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).

Atomo Diagnostics Limited has secured a significant order worth approximately $450,000 from the National Association of People with HIV Australia (NAPWHA) for HIV Self-Tests. This order is part of a government-funded initiative to increase HIV testing rates among high-risk groups, facilitated by partnerships with organizations like Grindr. The expansion of the program highlights the growing demand for at-home sexual health testing, reflecting a broader public health strategy to manage HIV more effectively.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian medical device company that provides unique, integrated rapid diagnostic test devices to the global market. Their patented devices are designed to simplify testing procedures, enhance usability, and improve reliability for both point-of-care and at-home testing applications. The company has commercialized various products internationally, focusing on infectious diseases, sexual health, and female health.

Average Trading Volume: 489,307

Technical Sentiment Signal: Sell

Current Market Cap: A$12.35M

For an in-depth examination of AT1 stock, go to TipRanks’ Stock Analysis page.